CN Patent

CN112638392B — 组合疗法

Assigned to ADC Therapeutics SA · Expires 2024-09-10 · 2y expired

What this patent protects

本公开涉及用于治疗诸如癌症的病理疾患的组合疗法。具体而言，本公开涉及组合疗法，所述组合疗法包括使用抗CD19抗体药物缀合物(抗CD19ADC)和抗BCL‑2剂治疗。

USPTO Abstract

本公开涉及用于治疗诸如癌症的病理疾患的组合疗法。具体而言，本公开涉及组合疗法，所述组合疗法包括使用抗CD19抗体药物缀合物(抗CD19ADC)和抗BCL‑2剂治疗。

Drugs covered by this patent

cobimetinib-fumarate (COBIMETINIB FUMARATE)

Patent Metadata

Patent number: CN112638392B
Jurisdiction: CN
Classification: —
Expires: 2024-09-10
Drug substance claim: No
Drug product claim: No
Assignee: ADC Therapeutics SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.